The Rubicon Research IPO marks the market entry of one of India’s established pharmaceutical research and manufacturing companies. With a strong focus on R&D and differentiated formulations, Rubicon Research operates across India, the US, and key global markets.
This IPO provides investors with an opportunity to participate in a fast-growing pharmaceutical R&D and formulations player, backed by global clientele and a robust product pipeline.
Rubicon Research IPO – Event Schedule
| Event | Date |
|---|---|
| IPO Open Date | October 9, 2025 (Thursday) |
| IPO Close Date | October 13, 2025 (Monday) |
| Allotment Finalization | October 14, 2025 (Tuesday) |
| Refunds / Unblocking of Funds | October 15, 2025 (Wednesday) |
| Credit of Shares to Demat | October 15, 2025 (Wednesday) |
| Listing Date | October 16, 2025 (Thursday) |
| UPI Mandate Cut-off | 5 PM, October 13, 2025 |
Rubicon Research IPO – Structure and Key Details
- Company: Rubicon Research Limited
- Industry: Pharmaceuticals – Contract Development & Manufacturing (CDMO)
- Offer Type: Combination of Fresh Issue + Offer for Sale
- Fresh Issue: ₹200 crore
- Offer for Sale (OFS): Up to 61,98,865 equity shares by selling shareholders
- Face Value: ₹10 per share
- Listing: NSE and BSE
- Book Running Lead Managers: ICICI Securities, DAM Capital Advisors, SBI Capital Markets
- Registrar: Link Intime India Pvt Ltd
Company Overview
Founded in 2001, Rubicon Research Limited is a pharmaceutical company focused on R&D-led product development, licensing, and contract manufacturing.
Business Highlights:
- Operations in India, the US, and Canada, with regulatory approvals from USFDA, MHRA, Health Canada.
- Products in multiple therapeutic categories including gastro, pain, respiratory, dermatology, and ophthalmic.
- Over 50 commercialized products and 70+ patents filed globally.
- Partnerships with global pharma players for contract development and contract manufacturing.
- Specialized in complex generics, novel drug delivery systems, and specialty pharma.
Rubicon operates three facilities in India, including its main R&D and manufacturing facility at Ambernath, Maharashtra.
Rubicon Research IPO – Financial Information
(₹ in Crores, Consolidated, as per DRHP)
| Particulars | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue from Operations | ₹249.3 Cr | ₹277.6 Cr | ₹326.4 Cr |
| EBITDA | ₹59.8 Cr | ₹62.1 Cr | ₹78.5 Cr |
| Net Profit (PAT) | ₹15.9 Cr | ₹21.7 Cr | ₹33.4 Cr |
| Net Worth | ₹226.5 Cr | ₹248.7 Cr | ₹286.9 Cr |
| RoE | 7.0% | 8.7% | 11.6% |
Highlights:
- Revenue grew ~31% from FY22 to FY24.
- PAT more than doubled in 3 years, showing scalability.
- RoE improved steadily, touching 11.6% in FY24.
- Strong EBITDA margins above 20%.
Objects of the Issue
The Fresh Issue proceeds of ₹200 crore will be used for:
- Repayment/prepayment of borrowings.
- Funding working capital requirements.
- General corporate purposes.
Industry Outlook
- The Indian pharmaceutical market is projected to reach US$130 billion by 2030, driven by exports and domestic demand.
- Growing demand for complex generics and specialty drugs.
- Global CDMO industry is booming, with India emerging as a low-cost, high-quality partner.
- Increasing outsourcing by large pharma to specialized CDMOs like Rubicon.
Key Risks
- Heavy dependence on regulatory approvals (USFDA, MHRA).
- Intense competition in generics and CDMO space.
- Currency fluctuations due to export revenues.
- Client concentration risk in contract manufacturing.
Allotment Status
Investors can check their Rubicon Research IPO allotment status via Link Intime portal using:
- PAN
- DP/Client ID
- Application Number
Conclusion
The Rubicon Research IPO offers investors exposure to a R&D-driven pharmaceutical company with strong global presence, increasing revenues, and a growing portfolio of specialty products.
The company has shown consistent growth in revenues and profitability, with improving margins and returns. While regulatory and competitive risks exist, Rubicon’s strong pipeline and partnerships with global players provide a solid long-term outlook.
For retail investors seeking exposure to the pharmaceutical and CDMO industry, the Rubicon Research IPO is worth serious consideration.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
